Transition of care and health-related outcomes in pediatric-onset systemic lupus erythematosus

Arthritis Care and Research

Volumn 67, Issue 11, 2015, Pages 1521-1528

  Felsenstein, Susanna ^a   Reiff, Andreas O ^a,b   Ramanathan, Anusha ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BELIMUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; MYCOPHENOLATE MOFETIL; RITUXIMAB; STEROID; TACROLIMUS; TOCILIZUMAB;

ARTICLE; CHILD; CHILD HEALTH CARE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; EDUCATION; EMOTION; EMPLOYMENT; FEMALE; HEALTH CARE; HEALTH INSURANCE; HEALTH STATUS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MORBIDITY; PATIENT REFERRAL; PEDIATRICS; RETROSPECTIVE STUDY; RHEUMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; TELEPHONE INTERVIEW; UNEMPLOYMENT; ADULT; FOLLOW UP; HEALTH SURVEY; INTERVIEW; LUPUS ERYTHEMATOSUS, SYSTEMIC; ONSET AGE; PROCEDURES; TRANSITION TO ADULT CARE; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADULT; AGE OF ONSET; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HEALTH SURVEYS; HUMANS; INTERVIEWS AS TOPIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RETROSPECTIVE STUDIES; TRANSITION TO ADULT CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945363989     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22611     Document Type: Article

References (48)

1. Tucker LB, Cabral DA., Transition of the adolescent patient with rheumatic disease: issues to consider. Rheum Dis Clin North Am 2007; 33: 661-72.
2. Falcini F, Nacci F., Systemic lupus erythematosus in the young: the importance of a transition clinic. Lupus 2007; 16: 613-7.
3. Bender BG., Risk taking, depression, adherence, and symptom control in adolescents and young adults with asthma. Am J Respir Crit Care Med 2006; 173: 953-7.
4. Quinn CT, Miller ST., Risk factors and prediction of outcomes in children and adolescents who have sickle cell anemia. Hematol Oncol Clin North Am 2004; 18: 1339-54.
5. Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA., Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010; 303: 1288-94.
6. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR., Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115: 3447-52.
7. Lotstein DS, Seid M, Klingensmith G, Case D, Lawrence JM, Pihoker C, et al., Transition from pediatric to adult care for youth diagnosed with type 1 diabetes in adolescence. Pediatrics 2013; 131: e1062-70.
8. Luyckx K, Moons P, Weets I., Self-classification as an adult in patients with type 1 diabetes: relationships with glycemic control and illness coping. Patient Educ Couns 2011; 85: 245-50.
9. Rausch JR, Hood KK, Delamater A, Schroff Pendley J, Rohan JM, Reeves G, et al., Changes in treatment adherence and glycemic control during the transition to adolescence in type 1 diabetes. Diabetes Care 2012; 35: 1219-24.
10. Nasr SZ, Campbell C, Howatt W., Transition program from pediatric to adult care for cystic fibrosis patients. J Adolesc Health 1992; 13: 682-5.
11. Kreindler JL, Miller VA., Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care. Patient Prefer Adherence 2013; 7: 1221-6.
12. Fair CD, Sullivan K, Dizney R, Stackpole A., "It's like losing a part of my family": transition expectations of adolescents living with perinatally acquired HIV and their guardians. AIDS Patient Care STDS 2012; 26: 423-9.
13. Vijayan T, Benin AL, Wagner K, Romano S, Andiman WA., We never thought this would happen: transitioning care of adolescents with perinatally acquired HIV infection from pediatrics to internal medicine. AIDS Care 2009; 21: 1222-9.
14. Minden K, Klotsche J, Nieworth M, Zink A, Horneff G., The health status of patients with juvenile idiopathic arthritis (JIA) significantly worsens after transfer from pediatric to adult care [abstract]. Arthritis Rheum 2014; 66 Suppl 11: 1268-9.
15. Hersh AO, Trupin L, Yazdany J, Panopalis P, Julian L, Katz P, et al., Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62: 1152-9.
16. Kamphuis S, Silverman ED., Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010; 6: 538-46.
17. Jordan L, Swerdlow P, Coates TD., Systematic review of transition from adolescent to adult care in patients with sickle cell disease. J Pediatr Hematol Oncol 2013; 35: 165-9.
18. Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al., Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009; 61: 13-20.
19. Tucker LB, Uribe AG, Fernandez M, Vila LM, McGwin G, Apte M, et al., Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008; 17: 314-22.
20. Hersh AO, Pang S, Curran ML, Milojevic DS, von Scheven E., The challenges of transferring chronic illness patients to adult care: reflections from pediatric and adult rheumatology at a US academic center. Pediatr Rheumatol Online J 2009; 7: 13.
21. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al., Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
22. Hersh A, von Scheven E, Yelin E., Adult outcomes of childhood-onset rheumatic diseases. Nat Rev Rheumatol 2011; 7: 290-5.
23. Zelko F, Beebe D, Baker A, Nelson SM, Ali A, Cedeno A, et al., Academic outcomes in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 1167-74.
24. Garris C, Oglesby A, Sulcs E, Lee M., Impact of systemic lupus erythematosus on burden of illness and work productivity in the United States. Lupus 2013; 22: 1077-86.
25. Baker K, Pope J, Fortin P, Silverman E, Peschken C., Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus 2009; 18: 1281-8.
26. Jacob CO, Reiff A, Armstrong DL, Myones BL, Silverman E, Klein-Gitelman M, et al., Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum 2007; 56: 4164-73.
27. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
28. Liang MH, Socher SA, Larson MG, Schur PH., Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-18.
29. Barsalou J, Levy DM, Silverman ED., An update on childhood-onset systemic lupus erythematosus. Curr Opin Rheumatol 2013; 25: 616-22.
30. Bandeira M, Buratti S, Bartoli M, Gasparini C, Breda L, Pistorio A, et al., Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. Lupus 2006; 15: 515-20.
31. Gutierrez-Suarez R, Ruperto N, Gastaldi R, Pistorio A, Felici E, Burgos-Vargas R, et al., A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2989-96.
32. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM., Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-44.
33. Miettunen PM, Ortiz-Alvarez O, Petty RE, Cimaz R, Malleson PN, Cabral DA, et al., Gender and ethnic origin have no effect on longterm outcome of childhood-onset systemic lupus erythematosus. J Rheumatol 2004; 31: 1650-4.
34. Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR, et al., Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003; 49: 501-7.
35. Zonana-Nacach A, Camargo-Coronel A, Yanez P, de Lourdes Sanchez M, Jimenez-Balderas FJ, Aceves-Avila J, et al., Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 119-23.
36. Boros CA, Bradley TJ, Cheung MM, Bargman JM, Russell JL, McCrindle BW, et al., Early determinants of atherosclerosis in paediatric systemic lupus erythematosus. Clin Exp Rheumatol 2011; 29: 575-81.
37. Schanberg LE, Sandborg C, Barnhart HX, Ardoin SP, Yow E, Evans GW, et al., Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the Atherosclerosis Prevention in Pediatric Lupus Erythematosus cohort. Arthritis Rheum 2009; 60: 1496-507.
38. Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, et al., Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15: 198-206.
39. Cook CD, Wedgwood RJ, Craig JM, Hartmann JR, Janeway CA., Systemic lupus erythematosus: description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics 1960; 26: 570-85.
40. Brunner HI, Huggins J, Klein-Gitelman MS., Pediatric SLE: towards a comprehensive management plan. Nat Rev Rheumatol 2011; 7: 225-33.
41. Ippolito A, Petri M., An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol 2008; 26 Suppl 51: S72-9.
42. Bono L, Cameron JS, Hicks JA., The very long-term prognosis and complications of lupus nephritis and its treatment. QJM 1999; 92: 211-8.
43. O'Connor KS, Brooks KS, Nysse-Carris KL, Skalland BJ, Sipulski ET, Costanzo DM., Design and operation of the Survey of Adult Transition and Health, 2007. Vital Health Stat 1 2011; 52: 1-85.
44. McGill M., How do we organize smooth, effective transfer from paediatric to adult diabetes care? Horm Res 2002; 57 Suppl 1: 66-8.
45. Levy M, Montes de Oca M, Claude-Babron M., Unfavorable outcomes (end stage renal failure/death) in childhood onset systemic lupus erythematosus: a multicenter study in Paris and ist environs. Clin Exp Rheumatol 1994; 12 Suppl 10: S63-8.
46. Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, et al., Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus cohort. Arthritis Rheum 2012; 64: 2356-65.
47. State of California Employment Development Department. URL: http://www.labormarketinfo.edd.ca.gov/Content.
48. Yelin E, Tonner C, Trupin L, Gansky SA, Julian L, Katz P, et al., Longitudinal study of the impact of incident organ manifestations and increased disease activity on work loss among persons with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012; 64: 169-75.